Application of bolA gene overexpression to increase outer membrane vesicle production

By constructing a VcCAST bidirectional mixed library in Escherichia coli, overexpressing bolA, qcl, and degQ, and underexpressing rfaI and rffT, the problem of high-yield strain modification and screening in OMV production was solved, and OMV yield and heterologous protein packaging capacity were significantly improved, supporting industrial applications.

CN123063422APending Publication Date: 2026-11-10TSINGHUA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611390013.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-08
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies for OMV production and modification suffer from limitations such as limited modification range of high-yield strains, lack of genome-wide screening tools, low throughput and high cost of screening methods, and difficulty in achieving rapid industrial-scale breeding of strains, especially in terms of two-way gene screening.

Method used

A genome-scale bidirectional mixed library was constructed in Escherichia coli Nissle 1917 using the Vibrio cholerae CRISPR-associated transposase (VcCAST) system. By overexpressing proteins bolA, qcl, and degQ and underexpressing proteins rfaI and rffT, exogenous promoters were inserted or genes were blocked using the CRISPR-associated transposase system to improve OMV yield and heterologous protein packaging capacity.

Benefits of technology

It significantly improved the yield of outer membrane vesicles and the heterologous protein packaging capacity of Escherichia coli, realizing efficient regulation and high-throughput screening of OMV biosynthesis, and supporting industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This application relates to the technical field of outer membrane vesicle preparation, specifically disclosing an application of bolA gene overexpression to increase outer membrane vesicle yield. The use of overexpressed and / or underexpressed proteins for increasing the yield of outer membrane vesicles (OMV) in *E. coli* is also disclosed; wherein the target protein in the overexpressed protein is selected from any one or more of the following group: degQ, qcl, and bolA; wherein the target protein in the underexpressed protein is rfaI and / or rffT. By overexpressing and / or underexpressing specific proteins in *E. coli*, it was unexpectedly found that the yield of outer membrane vesicles could be significantly increased, and the packaging of exogenous proteins within the outer membrane vesicles could be significantly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the technical field of outer vesicle preparation, specifically to the application of bolA gene overexpression to increase outer membrane vesicle yield. Background Technology

[0002] Outer membrane vesicles (OMVs) are nanoscale vesicles naturally secreted by Gram-negative bacteria, with a diameter of 50-250 nm. They can carry substances such as proteins, nucleic acids, and lipids, and have important applications in vaccine development, tumor immunology, intestinal targeted delivery, and in vivo therapeutic drugs.

[0003] Currently, OMV production and modification face the following bottlenecks: 1. High-yield strain modification mainly relies on single gene knockout (such as ΔnlpI, Δtol / pal), with limited yield increases; 2. There is a lack of genome-wide large-scale bidirectional screening tools that simultaneously cover gene knockout and gene overexpression; 3. Traditional genome-wide screening of OMV relies on LPS immunoblotting, which suffers from low throughput, long cycle time, and high cost; 4. Furthermore, no potent regulatory factors that can control OMV biogenesis have yet been discovered.

[0004] Genome-scale functional genomics screening is crucial for systematically defining genotype-phenotype relationships, elucidating the functions of unknown genes, and discovering novel targets for microbial strain engineering. Early genome-wide screening relied on array-based single-gene knockout or overexpression libraries, which provided comprehensive and accurate data, but these methods were labor-intensive and costly. Subsequently, high-throughput genome-wide screening was achieved using hybrid libraries, including transposon-based knockout libraries, recombinase-based transcriptional regulation libraries, dCas9-based repression libraries, dCas9 base editor-based knockout libraries, and CRISPR-associated transposase (CAST)-based knockout and overexpression libraries.

[0005] Overall, the main method for screening high-yield OMV strains still relies on host homologous recombination. However, the library construction for this method is cumbersome and time-consuming. In general, it can only screen one direction (i.e., screening gene knockout or screening gene overexpression), and cannot fully analyze the genotype-phenotype relationship. In addition, OMV screening methods have low throughput and poor accuracy, making it difficult to achieve rapid breeding of industrial strains.

[0006] Therefore, achieving bidirectional gene screening is one of the current research directions. Bidirectional genome screening integrates gene knockout / repression and gene overexpression into a single library to enable a more comprehensive study of phenotype-related genotypes. This approach has been well validated in mammalian cells. Although similar strategies have been developed for prokaryotes using recombinase systems or dxCas9-CRP regulatory systems, they are still significantly limited. Recombinase-based libraries require high homologous recombination efficiency in the host strain and involve complex library construction processes. Conversely, while Cas9-CRP-based libraries offer a simplified workflow and broad portability across different strains, their performance in high-throughput co-screening has not been fully demonstrated. In contrast, CAST-based systems facilitate gene knockout and overexpression while achieving genome integration independently of host recombination mechanisms in a variety of prokaryotes. Therefore, CAST-based hybrid libraries for simultaneous gene knockout and overexpression represent a powerful and promising tool for whole-genome screening in prokaryotes. Summary of the Invention

[0007] In this application, we constructed a genome-scale bidirectional mixed library in *Escherichia coli* Nissle 1917 (EcN) using the *Vibrio cholerae* CRISPR-associated transposase (VcCAST) system, achieving gene knockout (89.4% integration rate) and overexpression (87.5% integration rate). Analysis of this library revealed that bolA overexpression significantly promoted OMV biosynthesis and significantly enhanced OMV's ability to package heterologous proteins.

[0008] This application involves the following: 1. Use of overexpressed and / or underexpressed proteins to increase the production of outer membrane vesicles (OMV) in Escherichia coli; The target protein in the overexpressed protein is selected from any one or more of the following groups: bolA, qcl, and degQ; The target proteins in the low-expression proteins are rfaI and / or rffT.

[0009] 2. A method for increasing the yield of outer membrane vesicles (OMV) in Escherichia coli, comprising: Overexpression of any one or more of bolA, qcl, and degQ in E. coli to obtain overexpressed recombinant E. coli; and / or, This resulted in low expression of rfaI and / or rffT in E. coli, yielding recombinant E. coli with low expression.

[0010] 3. The method according to item 2, wherein the method for overexpressing any one or more target proteins among bolA, qcl and degQ in Escherichia coli is: increasing the copy number of the coding gene of the target protein, and / or increasing the expression level of the coding gene of the target protein; Preferably, the method for increasing the copy number of the coding gene of the target protein is: increasing the copy number of the coding gene of the target protein on the chromosome of the Escherichia coli, and / or inserting a foreign plasmid containing the coding gene of the target protein; More preferably, the method for increasing the copy number of the gene encoding the target protein on the chromosome in the *E. coli* is selected from: gene homologous recombination and Mu-driven integration; or Preferably, the method for increasing the expression level of the gene encoding the target protein includes: increasing the expression level of the gene encoding the target protein by modifying the expression regulatory region of the gene encoding the target protein; More preferably, the expression regulatory region includes any one or more regulatory elements from the group consisting of: promoters, enhancers, anti-termination signals, ribosome binding sites (RBS), and other expression control elements (e.g., regions where repressors or inducers bind, and / or binding sites of transcription and translation regulatory proteins).

[0011] In some implementations, the promoter is selected from any one of the J23 series promoters, T7 promoters, lacP promoters, trpP promoters, and λPL promoters.

[0012] 4. According to the use described in item 3, wherein the method for overexpressing any one or more target proteins of bolA, qcl and degQ in Escherichia coli is: by inserting an exogenous promoter to increase the expression level of the gene encoding the target protein; Preferably, the method for inserting the exogenous promoter includes: inserting the exogenous promoter using a CRISPR-associated transposase system.

[0013] 5. According to the use described in item 4, wherein donor plasmid L022 and effect plasmid L106-noncoding are simultaneously inserted into Escherichia coli to obtain overexpressing recombinant Escherichia coli; Culture the overexpressing recombinant Escherichia coli; After the donor plasmid L022 and the effect plasmid L106-noncoding were co-expressed in E. coli, the exogenous promoter was inserted into the E. coli via a CRISPR-associated transposase system to overexpress the target protein.

[0014] 6. The method according to item 5, wherein the effector plasmid L106-noncoding comprises an L106 vector and an sgRNA targeting the non-coding region of the target protein, and the donor plasmid L022 contains the exogenous promoter; Preferably, the target protein is selected from any one or more of the following group: degQ, qcl, and bolA; And / or, The sequence of the donor plasmid L022 is shown in SEQ ID NO:2; and / or The sequence of the L106 vector is shown in SEQ ID NO:3; and / or The sequence of the sgRNA targeting the bolA uncoding region is shown in SEQ ID NO:33 and / or SEQ ID NO:34, and / or The sequences of sgRNAs targeting the qcl untranslated region are shown in SEQ ID NO:31 and / or SEQ ID NO:32, and / or The sgRNA sequence targeting the degQ uncoding region is selected from any one or more of SEQ ID NOs:20~30; preferably SEQ ID NO:27.

[0015] 7. The use according to item 3, wherein the method for causing low expression of rfaI and / or rffT proteins in Escherichia coli is selected from: gene knockout, gene silencing, or the introduction of a blocking expression gene that causes low expression of said target protein into the gene encoding the target protein; Preferably, the method for achieving low expression of rfaI and / or rffT proteins in Escherichia coli is to introduce an expression-blocking gene that causes low expression of the target protein into the gene encoding the target protein. More preferably, the method for introducing a blocking expression gene that causes low expression of the target protein into the coding gene of the target protein is to insert the blocking expression gene using a CRISPR-associated transposase system.

[0016] 8. The method for inserting the gene blocking expression using the CRISPR-associated transposase system according to the use described in item 7 comprises: Simultaneous recombination of donor plasmid L009 and effect plasmid L106-coding in E. coli yielded low-expression recombinant E. coli; Culture the low-expression recombinant Escherichia coli; After the donor plasmid L009 and effect plasmid L106-coding are co-expressed in the *E. coli*, the blocking expression gene is inserted into the *E. coli* via a CRISPR-associated transposase system to achieve low expression of the target protein.

[0017] 9. The use according to item 8, wherein the effector plasmid L106-coding comprises an L106 vector and an sgRNA encoding the target protein, and the donor plasmid L009 contains the blocking expression gene; Preferably, the target protein is rfaI and / or rffT; and / or The sequence of the donor plasmid L009 is shown in SEQ ID NO:1; and / or The sequence of the L106 vector is shown in SEQ ID NO:3; and / or The sgRNA sequence targeting the rfaI coding region is selected from any one or more of SEQ ID NOs:4-6; and / or The sgRNA sequence targeting the rffT coding region is selected from any one or more of SEQ ID NOs:7~10.

[0018] 10. A recombinant Escherichia coli obtained by any one of items 2 to 9.

[0019] 11. Use of overexpression of bolA protein to increase the yield of outer membrane vesicles (OMV) in Escherichia coli and / or to enhance the heterologous protein packaging capacity of outer membrane vesicles (OMV).

[0020] 12. According to the use described in item 11, the heterologous protein is selected from any one or more of the group consisting of: ClyA, OmpA, OmpX, OmpC, OmpF, AIDA-I, InaV, FimH, FimA and NLP42.

[0021] 13. A method for improving the packaging ability of heterologous proteins, comprising: This allows bolA to be overexpressed in E. coli, resulting in overexpressed recombinant E. coli. The recombinant Escherichia coli was used to express the heterologous protein; Preferably, the heterologous protein is selected from any one or more of the following group: ClyA, OmpA, OmpX, OmpC, OmpF, AIDA-I, InaV, FimH, FimA and NLP42.

[0022] 14. The method according to item 13, wherein the method for overexpressing bolA in Escherichia coli is to: increase the copy number of the gene encoding the target protein of bolA, and / or increase the expression level of the gene encoding the target protein of bolA; Preferably, the method for increasing the copy number of the gene encoding the bolA target protein is: increasing the copy number of the gene encoding the bolA target protein on the chromosome of the Escherichia coli, and / or inserting a foreign plasmid containing the gene encoding the bolA target protein; More preferably, the method for increasing the copy number of the gene encoding the bolA target protein on the chromosome of the *E. coli* is selected from: homologous recombination and Mu-driven integration; or Preferably, the method for increasing the expression level of the gene encoding the bolA target protein includes: increasing the expression level of the gene encoding the bolA target protein by modifying the expression regulatory region of the gene encoding the bolA target protein; More preferably, the expression regulatory region includes any one or more regulatory elements from the group consisting of: promoters, enhancers, anti-termination signals, ribosome binding sites (RBS), and other expression control elements (e.g., regions where repressors or inducers bind, and / or binding sites of transcription and translation regulatory proteins).

[0023] In some implementations, the promoter is selected from any one of the J23 series promoters, T7 promoters, lacP promoters, trpP promoters, and λPL promoters.

[0024] 15. According to the use described in item 13, wherein the method for overexpressing bolA in Escherichia coli is: by inserting an exogenous promoter to increase the expression level of the gene encoding the target protein of bolA; Preferably, the method for inserting the exogenous promoter includes: inserting the exogenous promoter using a CRISPR-associated transposase system.

[0025] 16. The use according to item 15, wherein the donor plasmid L022 and the effect plasmid L106-noncoding are simultaneously inserted into Escherichia coli to obtain overexpressing recombinant Escherichia coli; Culture the overexpressing recombinant Escherichia coli; After the donor plasmid L022 and the effect plasmid L106-noncoding were co-expressed in E. coli, the exogenous promoter was inserted into the E. coli via a CRISPR-associated transposase system to overexpress the bolA target protein.

[0026] 17. The method according to claim 16, wherein the effector plasmid L106-noncoding comprises an L106 vector and an sgRNA targeting the non-coding region of the target protein, and the donor plasmid L022 contains the exogenous promoter; And / or, The sequence of the donor plasmid L022 is shown in SEQ ID NO:2; and / or The sequence of the L106 vector is shown in SEQ ID NO:3; and / or The sequence of the sgRNA targeting the bolA uncoding region is shown in SEQ ID NO:33 and / or SEQ ID NO:34.

[0027] Beneficial effects This application is the first to unexpectedly discover, through low or overexpression of a specific protein in *E. coli*, that engineered *E. coli* can exhibit a significantly increased yield of outer membrane vesicles. In particular, overexpression of bolA significantly increases the yield of outer membrane vesicles in *E. coli*.

[0028] Further research by the applicant revealed that overexpression of bolA significantly enhances the heterologous protein packaging capacity of outer membrane vesicles (OMVs). Attached Figure Description

[0029] Figure 1 Design and construction of a genome-wide bidirectional library of *Escherichia coli* Nissle 1917 (EcN) based on VcCAST. Among other things, Figure 1 A. Schematic diagram of constructing a hybrid library integrating gene knockout and overexpression. The sgRNA paired with plasmid L009 (for gene inactivation) is used for gene knockout, while the sgRNA binding to L022 (for gene activation) drives gene activation. The resulting sub-libraries are merged to form a bidirectional hybrid library. Figure 1 The architecture of the B.VcCAST editing system includes donor plasmids L009 (for gene inactivation) and L022 (for gene activation), as well as the coding sgRNA effector plasmid L106 and the non-coding sgRNA effector plasmid L106.

[0030] Figure 2 Coverage statistics of sgRNA libraries. Among them, Figure 2 A. Coverage statistics of coding sgRNA libraries. Figure 2 B. Coverage statistics of non-coding sgRNA libraries.

[0031] Figure 3 Genome-scale screening identified genetic regulators of outer membrane vesicle (OMV) biogeneration in *E. coli* Nissle 1917 (EcN). Among them, Figure 3 A. Schematic diagram of DNA proxy screening strategy in exosome biogenesis. Exosome yield is inferred by comparing the relative abundance of sgRNA plasmids in exosomes with the proportion of the total bacterial population. Figure 3B. Genome-wide distribution of sites significantly associated with changes in exosome biochemistry. Figure 3 C. Through quantitative standardization of OD 600 Exosome production was used to validate candidate genes. Data are presented as mean ± standard deviation (n=3 biological replicates); **P<0.01, ***P<0.001; ns, not significant. Figure 3 A and Figure 3 B obtains OMV (i.e., exosomes) using the method described in "OMV biogenesis"; Figure 3 C and Figure 3 A or Figure 3 The difference with B is that it is finally obtained by ultracentrifugation at 174900g for 2 hours, without dilution after precipitation with ammonium sulfate.

[0032] Figure 4 Characterization and mechanism analysis of OMV produced by EcN bolA. Among them, Figure 4 A. SDS-PAGE analysis of wild-type EcN and bolA-overexpressing EcN-purified outer membrane vesicles (OMVs) showed increased abundance of major outer membrane proteins. Figure 4 B. Transmission electron microscopy (TEM) images of OMVs in wild-type EcN and bolA-overexpressing strains, showing increased OMV abundance with bolA overexpression. Scale bar, 500 nm. Figure 4 C. Nanoflow cytometry (nFCM) quantification of OMV particle number showed that bolA overexpression increased particle number and decreased vesicle size. Data are expressed as mean ± standard deviation (n=3 biological replicates); **P<0.01, ***P<0.001. Figure 4 D. OMV yield under different schemes; % , where the sgRNA targeting the gmd gene is shown in SEQ ID NO:35, and the sgRNA targeting the arnC gene is shown in SEQ ID NO:36. Data are expressed as mean ± standard deviation (n=3 biological replicates); ***P<0.001. In the figures, EcN is the experimental group without gene knockout or overexpression modification; EcN bolA is the experimental group with bolA gene overexpression; EcN bolA gmd is the experimental group where the bolA gene is overexpressed and the gmd gene is knocked out; EcN bolA arnC is the experimental group with bolA gene overexpression and arnC gene knockout. Among them, Figure 4 A to Figure 4 C obtains OMV (i.e., exosomes) using the method described in "OMV biogenesis"; Figure 4 D and Figure 4 A (or Figure 4The difference between B and 4C is that the final product is obtained by ultracentrifugation at 174900g for 2 hours, without dilution after precipitation with ammonium sulfate.

[0033] Figure 5 Reproducibility and enrichment analysis of OMV biosynthesis screening and bolA mechanism. Figure 5 A. Correlation analysis between two biological replicates after OMV biosynthesis screening showed a Pearson correlation coefficient r = 0.785. Figure 5 B. Lorenz curve analysis of sgRNA distribution before and after OMV screening. Figure 5 C. Western blot analysis of heterologous protein (ClyA) packaging in OMV from WT EcN and bolA overexpressing EcN. Figure 5 D. Quantification of OMV-related plasmid DNA copy number in engineered strains. Figure 5 A serial dilution spot assay was performed on WT EcN and bolA strains overexpressing EcN under E. SDS stress. The specific experimental method was as follows: 1 g of sodium dodecyl sulfate (SDS) was dissolved in 10 ml of water and filtered through a 0.22 μm filter to obtain a 10% SDS stock solution. 150 μL of the 10% SDS was added to 15 ml of melted solid LB agar, and plates were poured to obtain LB agar plates containing 0.1% SDS. EcN and EcN bolA strains cultured overnight were serially diluted 10-fold with sterile PBS and spotted onto LB agar plates and LB agar plates containing 0.1% SDS, respectively. After overnight incubation at 37°C, observations were performed. In the attached figure, EcN represents the experimental group without gene knockout or overexpression modification; EcN... rfaI is the experimental group where the rfaI gene was knocked out; EcN rfft is the experimental group where the rfft gene was knocked out; EcN nlpI is the experimental group with nlpI gene knockout; EcN ctp is the experimental group with ctp gene knockout; EcN degQ is the experimental group with degQ gene overexpression; EcN qcl is the experimental group with qcl gene overexpression; EcN bolA is the experimental group with bolA gene overexpression.

[0034] Figure 6 Further Western blot analysis of heterologous protein (ClyA) packaging in OMV from WT EcN and bolA overexpressing EcN. The figure shows 50 µl of concentrated OMV obtained after OMV separation and purification from 50 mL of fermentation broth containing OMV. The volume shown is the volume taken from the 50 µl concentrated OMV used for protein blot analysis. Detailed Implementation

[0035] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in their functions.

[0036] As used throughout the specification and claims, the terms "comprising" or "including" are open-ended and should be interpreted as "comprising but not limited to". The subsequent descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0037] It should be understood that the embodiments of this application described herein include embodiments that are "composed of" and / or "substantially composed of". References to values ​​or parameters of "about" herein include (and describe) variations of that value or parameter itself. For example, a reference to "about X" includes a description of "X".

[0038] As used herein, references to “not” values ​​or parameters generally refer to and describe “except” values ​​or parameters. For example, “The method is not used to treat type X cancer” means that the method is used to treat cancers other than type X.

[0039] As used in this article, the term “approximately XY” has the same meaning as “approximately X to approximately Y”.

[0040] As used herein and in the appended claims, the singular forms “a / an” and “the” include the plural objects unless the context clearly indicates otherwise. It should also be noted that claims may be drafted to exclude any optional elements. Therefore, this statement is intended as a preliminary basis for the use of exclusive terms such as “only” or “merely” in conjunction with the description of the elements of the claim, or for the use of the limitation of “no”.

[0041] As used herein, the term "and / or" in words such as "A and / or B" is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, as used herein, the term "and / or" in words such as "A, B and / or C" is intended to include each of the following embodiments: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0042] As used herein, the term "identity" refers to the overall relevance between polymer molecules, such as nucleic acid molecules (e.g., DNA and / or RNA molecules) and / or polypeptide molecules. For example, the percentage identity of two nucleic acid sequences can be calculated by aligning the two sequences for optimal comparison purposes (e.g., for optimal alignment, vacancies can be introduced in one or both of the first and second nucleic acid sequences, and dissimilar sequences can be ignored for comparison purposes). In some embodiments, the length of the sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. Nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. Taking into account the number of vacancies and the length of each vacancy (which needs to be introduced to achieve optimal alignment of the two sequences), the percentage identity between the two sequences is a function of the number of identical positions shared by the sequences. Sequence comparison and determination of the percentage identity between two sequences can be accomplished using mathematical algorithms.

[0043] As used herein, the term "suppressed gene expression" refers to a reduction in the amount of the gene's expression product. The expression product can be RNA transcribed from a gene (e.g., mRNA) or a polypeptide translated from mRNA transcribed from a gene. Typically, a decrease in mRNA levels leads to a decrease in the level of the polypeptide translated from it. Gene expression levels can be determined using standard techniques for measuring mRNA and / or protein levels.

[0044] As used herein, the term “in vitro” refers to events that occur in an artificial environment, such as in a test tube or reaction vessel, in a cell culture, in a petri dish, etc., rather than within a living organism (e.g., an animal, plant, or microorganism).

[0045] As used herein, the term "in vivo" refers to events that occur within an organism (e.g., an animal, plant, or microorganism).

[0046] As used herein, the terms “extracellular vesicle,” “outer membrane vesicle,” “extracellular vesicle,” or “EV” refer to cell-derived vesicles containing a membrane enclosing their internal space, which are liquid droplets surrounded by a lipid bilayer. Extracellular membrane vesicles include all membrane-bound vesicles (e.g., exosomes, microvesicles, apoptotic bodies, tumor vesicles, nanovesicles, etc.) with a diameter smaller than that of the cell from which they originate. In some implementations, the diameter of the outer membrane vesicle is any diameter range within the range of 10~200nm, 10~180nm, 10~170nm, 10~160nm, 10~150nm, 10~140nm, 20~200nm, 20~190nm, 20~180nm, 20~170nm, 20~160nm, 20~150nm, 20~140nm, or 10~200nm; for example, it can be any diameter range within the range of 10nm, 20nm, 30nm, 40nm, 50nm, 60nm, 70nm, 90nm, 100nm, 110nm, 120nm, 130nm, 140nm, 150nm, 160nm, 170nm, 180nm, 190nm, 200nm, or 10~200nm. In this application, the extracellular membrane vesicle specifically refers to bacterial extracellular membrane vesicles; preferably, *E. coli* extracellular membrane vesicles. In some embodiments, the extracellular membrane vesicle may contain various macromolecular payloads within an internal space (i.e., a lumen), displayed on the outer surface of the extracellular vesicle, and / or transmembrane. In some embodiments, the payload may include nucleic acids, proteins, carbohydrates, lipids, small molecules, and / or combinations thereof. In some embodiments, the extracellular medium comprises a scaffold portion. By way of example, and not limitation, extracellular membrane vesicles include apoptotic bodies, cell debris, cell-derived vesicles obtained by direct or indirect manipulation (e.g., by continuous extrusion or treatment with an alkaline solution), vesicular organelles, and vesicles generated by living cells (e.g., by direct plasma membrane budding or late endosome fusion with the plasma membrane). Extracellular membrane vesicles may originate from living or dead organisms, explanted tissues or organs, prokaryotic or eukaryotic cells, and / or cultured cells. In some embodiments, the extracellular membrane vesicles are generated by cells expressing one or more transgenic products.

[0047] The term outer membrane vesicles includes microvesicles shed from cells as well as synthetically produced microvesicles. Outer membrane vesicles shed from cells typically contain antigenic components from the cell of origin. Outer membrane vesicles shed from cells also often contain an asymmetric distribution of phospholipids, reflecting the phospholipid distribution of the cell of origin.

[0048] The term "protein" is used interchangeably with the terms polypeptide and peptide herein, and refers to a polypeptide (i.e., a string of at least two amino acids linked together by peptide bonds). Proteins may include portions other than amino acids (e.g., may be glycoproteins) and / or may be otherwise processed or modified. Those skilled in the art will understand that a "protein" can be a complete polypeptide chain produced by a cell (with or without a signal sequence), or it can be its functional portion. Polypeptides may contain L-amino acids, D-amino acids, or both, and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, the addition of chemical entities such as carbohydrate groups, phosphate groups, farnesyl groups, isofarnesyl groups, fatty acid groups, amide groups, terminal acetyl groups, linkers for conjugation, functionalization, or other modifications (e.g., α-amidation), etc.

[0049] The term "recombination" refers to the process by which two or more nucleic acid molecules, or two or more regions of a single nucleic acid molecule, are modified by recombinase proteins. Recombination can in particular lead to the insertion, inversion, excision, or translocation of nucleic acid sequences, for example, within or between one or more nucleic acid molecules.

[0050] As used herein, a "vector" refers to a nucleic acid molecule that can transport another nucleic acid to which it is linked. In some embodiments, a vector can enable extrachromosomal replication and / or expression of the nucleic acids linked to it in host cells such as eukaryotic and / or prokaryotic cells. Vectors capable of directing the expression of operablely linked genes are referred to herein as "expression vectors".

[0051] As used in this article, the term "plasmid" refers to a DNA molecule other than chromosomes (or nucleoids) in organisms such as bacteria, yeast, and actinomycetes. It exists in the cytoplasm or nucleus, has the ability to replicate autonomously, and maintains a constant copy number in daughter cells, while expressing the genetic information it carries.

[0052] As used herein, the terms “silencing,” “inhibiting its expression,” “downregulating its expression,” “low expression,” etc., referring to rfaI, rffT, nlpI, or ctP proteins, refer in this context to at least partial inhibition of the expression of rfaI, rffT, nlpI, or ctP proteins. For example, inhibition of rfaI, rffT, nlpI, or ctP expression compared to a control can be demonstrated by a reduction in the amount of rfaI, rffT, nlpI, or ctP mRNA isolated or detected from a first cell or cell group (where rfaI, rffT, nlpI, or ctP is transcribed and has been or has been treated to inhibit the expression of rfaI, rffT, nlpI, or ctP). A control may be a second cell or cell group substantially identical to the first cell or cell group, except that the second cell or cell group has not been treated in this way (control cells). The degree of inhibition is usually expressed as a percentage of the control level. Alternatively, the degree of inhibition can be given by a reduction in a parameter associated with the functional expression of rfaI, rffT, nlpI, or ctP (e.g., the amount of protein encoded by the rfaI, rffT, nlpI, or ctP gene). A reduction in a parameter associated with the functional expression of rfaI, rffT, nlpI, or ctP can similarly be expressed as a percentage of the control level. In principle, changes in the expression levels of rfaI, rffT, nlpI, or ctP can be determined in any constitutively or genetically engineered cell expressing rfaI, rffT, nlpI, or ctP, and by any appropriate analysis. For example, in some embodiments, the expression of rfaI, rffT, nlpI, or ctP is inhibited by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, the expression of rfaI, rffT, nlpI, or ctP is suppressed by at least about 60%, 65%, 70%, 75%, or 80%. In some embodiments, the expression of rfaI, rffT, nlpI, or ctP is suppressed by at least about 85%, 90%, 95%, 98%, 99%, or more; for example, the expression of rfaI, rffT, nlpI, or ctP is suppressed by 100%, so that rfaI, rffT, nlpI, or ctP is not expressed.

[0053] As used herein, the terms "promote its expression," "upregulate its expression," "overexpression," etc., referring to the bolA, qcl, or degQ protein, mean at least partially promoting the expression of the bolA, qcl, or degQ protein. For example, in some embodiments, by selecting a suitable Cas protein and the sgRNA provided herein, the expression of bolA, qcl, or degQ is promoted by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, by selecting a suitable Cas protein and the sgRNA provided herein, the expression of bolA, qcl, or degQ is promoted by at least about 60%, 65%, 70%, 75%, or 80%. In some embodiments, the expression of bolA, qcl, or degQ is promoted by at least about 85%, 90%, 95%, 98%, 99%, or more; for example, 100%.

[0054] As used herein, the term "wildtype" has the meaning commonly understood by those skilled in the art as referring to the typical form of an organism, strain, gene, or trait that distinguishes it from mutants or variants when it exists in nature. It can be isolated from resources in nature and is not deliberately modified.

[0055] As used herein, the term "target protein" refers to a protein that is the intended or desired target of an intervention, action, or effect, which is the intervention of a method or composition that is intended or desired. In some embodiments, the target protein is a protein that is not expressed, poorly expressed, and / or overexpressed after treatment; for example, it may be proteins degQ, qcl, bolA, rfaI, rffT, nlpI, and / or ctP.

[0056] As used herein, the terms "heterologous protein" and "exogenous protein" are used interchangeably and include, when used in relation to a protein or polypeptide, referring to a protein or polypeptide that is engineered to introduce a nucleic acid molecule encoding the protein or polypeptide into a host genome, cell, or organism and is expressed in the host, cell, or organism.

[0057] As used herein, the term "coding region" refers to the region on a DNA molecule containing the coding sequence of an element that, after transcription, can be used to initiate or regulate the expression of said protein, polypeptide, or fragment thereof, including but not limited to the 5'UTR, 3'UTR, poly(A) tail (or poly(A) tail signal), etc. In some embodiments, the coding region contains the coding sequence of at least one untranslated region (UTR). In some embodiments, the coding region contains the coding sequence of at least the 5'UTR and the coding sequence of the target protein. In some embodiments, the coding region contains, from the 5' to the 3' of the DNA molecule, at least sequentially the coding sequence of the 5'UTR, the coding sequence of the target protein, the coding sequence of the 3'UTR, and the poly(A) tail signal (or the DNA sequence corresponding to the poly(A) tail sequence); furthermore, a start codon (5' end) and a stop codon (3' end) may be included at both ends of the coding sequence of the target protein, respectively.

[0058] As used herein, the “CRISPR-associated transposase system” comprises at least one Cas protein and one or more transposon-associated proteins. The transposon-associated proteins are selected from TnsA, TnsB, TnsC, or any combination thereof. The Cas protein is selected from Cas5, Cas6, Cas7, Cas8, or any combination thereof.

[0059] This application provides the use of an overexpressed and / or underexpressed protein for increasing the production of outer membrane vesicles (OMV) in Escherichia coli; The target protein in the overexpressed protein is selected from any one or more of the following groups: bolA, qcl, and degQ; The target protein in the low-expression protein is selected from any one or more of the following groups: rfaI, rffT, nlpI, and ctP.

[0060] This application also provides a method for increasing the yield of outer membrane vesicles (OMV) in Escherichia coli, comprising: Overexpression of any one or more of bolA, qcl, and degQ in E. coli to obtain overexpressed recombinant E. coli; and / or, This resulted in low expression of rfaI and / or rffT in E. coli, yielding recombinant E. coli with low expression.

[0061] In some embodiments, the method further includes: culturing the gene-overexpressing recombinant *E. coli* and isolating the outer membrane vesicles. The gene-overexpressing recombinant *E. coli* can be cultured using methods well-known to those skilled in the art, and there are no other special limitations on this culture method. The outer membrane vesicles can be isolated using methods well-known to those skilled in the art, and there are no other special limitations on this isolation method.

[0062] In some embodiments, the overexpressed protein is bolA. In some embodiments, the overexpressed protein is degQ. In some embodiments, the overexpressed protein is qcl. In some embodiments, the underexpressed protein is rfaI. In some embodiments, the underexpressed protein is rffT. In some embodiments, the underexpressed protein is nlpI. In some embodiments, the underexpressed protein is ctP. The applicant has found that overexpression of any one of degQ, qcl, and bolA can significantly increase the yield of outer membrane vesicles in *E. coli*; among which overexpression of bolA results in the highest yield of outer membrane vesicles in *E. coli*.

[0063] In some preferred embodiments, the target protein is bolA. The applicant has found, for example, to refer to... Figure 3 Compared to other target proteins, overexpression of bolA in E. coli can significantly increase the production of outer membrane vesicles; it is at least 6 times, or even 10 times, 12 times, or even 15 times higher than other proteins; and compared to untreated E. coli, its production of outer membrane vesicles is even 24 times, 26 times, or even 28 times higher.

[0064] In this application, there are no restrictions on the methods for achieving one or more of bolA, qcl, and degQ. Those skilled in the art can choose the appropriate method to achieve the overexpression of the target protein as needed.

[0065] In some implementations, the method for overexpressing any one or more target proteins of bolA, qcl, and degQ in Escherichia coli can be, for example, by increasing the copy number of the gene encoding the target protein; or by increasing the expression level of the gene encoding the target protein; or by simultaneously increasing both the copy number of the gene encoding the target protein and the expression level of the gene encoding the target protein.

[0066] For example, in some embodiments, the copy number of the coding gene of the target protein is increased by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to a target protein whose coding gene copy number is not increased. In some embodiments, the copy number of the coding gene of the target protein is increased by at least about 60%, 65%, 70%, 75%, or 80% compared to a target protein whose coding gene copy number is not increased. In some embodiments, the copy number of the coding gene of the target protein is increased by at least about 85%, 90%, 95%, 98%, 99%, or more compared to a target protein whose coding gene expression level is not increased. For example, in some embodiments, the expression level of the coding gene of the target protein is increased by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to a target protein whose coding gene expression level is not increased. In some embodiments, the expression level of the coding gene of the target protein is increased by at least about 60%, 65%, 70%, 75%, or 80% compared to a target protein whose coding gene expression level is not increased. In some implementations, the expression level of the gene encoding the target protein is increased by at least about 85%, 90%, 95%, 98%, 99% or more compared to the target protein whose gene expression level is not increased.

[0067] In some embodiments, the method for increasing the copy number of the gene encoding the target protein on the chromosome of *E. coli* is selected from homologous recombination and Mu-driven integration. For example, the gene encoding the target protein can be directly inserted into the *E. coli* chromosome at least 1 copy, 2 copies, 3 copies, or more copies via homologous recombination. Those skilled in the art can perform homologous recombination or Mu-driven integration using conventional methods.

[0068] In some embodiments, the method for increasing the expression level of the gene encoding the target protein includes: increasing the expression level of the gene encoding the target protein by modifying the expression regulatory region of the gene encoding the target protein. In some embodiments, the expression regulatory region contains any one or more regulatory elements from the group consisting of: promoters, enhancers, anti-termination signals, ribosome binding sites (RBS), and other expression control elements (e.g., regions where repressors or inducers bind, and / or binding sites of transcription and translation regulatory proteins). In some embodiments, the regulatory element in the expression regulatory region is a promoter. It should be noted that, in this application, the exogenous promoter inserted upstream of the coding gene of the target protein can be any promoter that enhances the expression of the coding gene, and there are no other restrictions in this application; for example, it can be a constitutive strong promoter, such as the J23 series homologous constitutive promoters (specifically, J23100~J23119); it can also be other strong promoters, such as the T7 promoter, lacP promoter, trpP promoter, and λPL promoter; non-limiting examples of the selected promoter can be any one of the J23 series promoters, T7 promoter, lacP promoter, trpP promoter, and λPL promoter.

[0069] In this application, the meanings of promoter, enhancer, anti-termination signal, ribosome binding site (RBS) and other expression control elements (e.g., regions where repressors or inducers bind, and / or binding sites of transcription and translation regulatory proteins) are as generally defined by those skilled in the art.

[0070] In this application, the method of inserting the exogenous promoter upstream of the coding gene of the target protein is a common practice for those skilled in the art and is not particularly limited. In some embodiments, exemplarily, the method of inserting the exogenous promoter includes: inserting the exogenous promoter using a CRISPR-associated transposase system. For example, refer to this application. Figure 1 B. The CRISPR-associated transposase system contains Cas proteins consisting of a combination of Cas6, Cas7, and Cas8; and transposon-associated proteins consisting of a combination of TnsA, TnsB, and TnsC.

[0071] Specifically, in some implementations, donor plasmid L022 and effect plasmid L106-noncoding are simultaneously inserted into E. coli to obtain overexpressed recombinant E. coli; Culture the overexpressing recombinant Escherichia coli; After the donor plasmid L022 and the effect plasmid L106-noncoding were co-expressed in E. coli, the exogenous promoter was inserted into the E. coli via a CRISPR-associated transposase system to overexpress the target protein.

[0072] In some embodiments, the effector plasmid L106-noncoding comprises an L106 vector and an sgRNA targeting the non-coding region of a target protein. In some embodiments, the donor plasmid L022 contains the exogenous promoter; in some embodiments, the donor plasmid L022 further comprises genes encoding Cas proteins (e.g., a combination of Cas6, Cas7, and Cas8) and genes encoding transposon-related proteins (e.g., a combination of TnsA, TnsB, and TnsC) (e.g., reference). Figure 1 B (right side).

[0073] In this application, a sequence is inserted into the upstream non-coding region of the target protein gene to achieve gene overexpression.

[0074] In some embodiments, the sgRNA targeting the non-coding region of the target protein is inserted into the L106 vector via an sgRNA insertion frame. In some embodiments, the sgRNA insertion frame comprises the following structure: insert sequence-sgRNA-insert sequence. In some embodiments, the sgRNA insertion frame has the following structure: insert sequence-sgRNA-insert sequence. In some embodiments, the insert sequence is as shown in SEQ ID NO:37; or has at least 80% sequence identity with the sequence shown in SEQ ID NO:37; for example, has 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence shown in SEQ ID NO:37.

[0075] In some implementations, the inserted sequence described above is a fixed sequence, which is part of the mature sgRNA. This inserted sequence (28 bp) and the sgRNA (32 bp, the variable region, used to identify the target location on the genome) are transcribed together, processed by the CAST enzyme into mature sgRNA, and form a complex with the CAST enzyme.

[0076] In some embodiments, the sequence of the donor plasmid L022 is as shown in SEQ ID NO:2; or has at least 80% sequence identity with the sequence shown in SEQ ID NO:2; for example, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence shown in SEQ ID NO:2. In some embodiments, the sequence of the L106 vector is as shown in SEQ ID NO:3; or has at least 80% sequence identity with the sequence shown in SEQ ID NO:3; for example, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence shown in SEQ ID NO:3.

[0077] In some embodiments, the sequence of the sgRNA targeting the bolA untranslated region is shown in SEQ ID NO:33 and / or SEQ ID NO:34. In some embodiments, the sequence of the sgRNA targeting the qcl untranslated region is shown in SEQ ID NO:31 and / or SEQ ID NO:32. In some embodiments, the sequence of the sgRNA targeting the degQ untranslated region is selected from any one or more of SEQ ID NOs:20-30. In some preferred embodiments, the sequence of the sgRNA targeting the degQ untranslated region is shown in SEQ ID NO:27.

[0078] In this application, *Escherichia coli* can be any strain of *E. coli* well-known or commonly used by those skilled in the art, without any other special limitations. For example, it can be a commonly used laboratory strain: a K-12 lineage derivative; specifically, it could be DH5α, JM109, TOP10, or MG1655. For example, it can be a commonly used laboratory strain: a B lineage derivative; specifically, it could be BL21(DE3) or BL21(DE3)pLysS. For example, it could also be HB101, Nissle 1917, or ATCC 25922. In some embodiments, the *E. coli* is *Escherichia coli* Nissle 1917 (EcN).

[0079] In some embodiments, the method for achieving low expression of rfaI and / or rffT proteins in *E. coli* is not limited, as long as it can inhibit the expression of the aforementioned genes. Non-limiting examples of this method include: gene knockout, gene silencing, or the introduction of a blocking expression gene that causes low expression of the target protein into the gene encoding the target protein. In some embodiments, the method for achieving low expression of rfaI and / or rffT proteins in *E. coli* is to introduce a blocking expression gene that causes low expression of the target protein into the gene encoding the target protein. In this application, there are no special limitations on the blocking expression gene, as long as it can prevent the normal expression of the target protein. For example, refer to... Figure 1 B. For example, the expression-blocking gene sfGFP is inserted into the coding gene of the target protein to disrupt the successful expression of the coding gene of the target protein, thereby achieving low expression of the target protein. In this application, the method of inserting the expression-blocking gene into the coding gene of the target protein is a common practice for those skilled in the art and is not particularly limited. In some embodiments, the method of introducing the expression-blocking gene that causes low expression of the target protein into the coding gene of the target protein is: inserting the expression-blocking gene using a CRISPR-associated transposase system.

[0080] In some embodiments, the method of inserting the gene that blocks expression using a CRISPR-associated transposase system includes: Simultaneous recombination of donor plasmid L009 and effect plasmid L106-coding in E. coli yielded low-expression recombinant E. coli; Culture the low-expression recombinant Escherichia coli; After the donor plasmid L009 and effect plasmid L106-coding are co-expressed in the *E. coli*, the blocking expression gene is inserted into the *E. coli* via a CRISPR-associated transposase system to achieve low expression of the target protein.

[0081] In some embodiments, the effector plasmid L106-coding comprises an L106 vector and sgRNA encoding the target protein. In some embodiments, the donor plasmid L009 contains the blocking expression gene; the blocking expression gene, after being inserted into the coding gene of the target protein, makes it difficult for the coding gene to be expressed normally, thereby achieving non-expression of the target protein. In some embodiments, the donor plasmid L009 also contains the coding gene of a Cas protein (e.g., a combination of Cas6, Cas7, and Cas8) and the coding gene of a transposon-related protein (e.g., a combination of TnsA, TnsB, and TnsC) (e.g., reference gene). Figure 1 (B, left side).

[0082] In some embodiments, the sgRNA targeting the coding region of the target protein is inserted into the L106 vector via an sgRNA insertion frame. In some embodiments, the sgRNA insertion frame comprises the following structure: insert sequence-sgRNA-insert sequence. In some embodiments, the sgRNA insertion frame has the following structure: insert sequence-sgRNA-insert sequence. In some embodiments, the insert sequence is as shown in SEQ ID NO:37; or has at least 80% sequence identity with the sequence shown in SEQ ID NO:37; for example, has 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence shown in SEQ ID NO:37.

[0083] In some embodiments, the target protein is rfaI; in some embodiments, the target protein is rffT; in some embodiments, the target protein is both rfaI and rffT. In some preferred embodiments, the target protein is ctP. The applicant has found, for example, to refer to Figure 3 Compared to rfaI, low expression of rffT, nlpI, or ctP in E. coli resulted in a more significant increase in outer membrane vesicle production.

[0084] In some embodiments, the sequence of the donor plasmid L009 is as shown in SEQ ID NO:1; or has at least 80% sequence identity with the sequence shown in SEQ ID NO:1; for example, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence shown in SEQ ID NO:1. In some embodiments, the sequence of the L106 vector is as shown in SEQ ID NO:3; or has at least 80% sequence identity with the sequence shown in SEQ ID NO:3; for example, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence shown in SEQ ID NO:3.

[0085] In some embodiments, the sgRNA sequence targeting the rfaI coding region is selected from any one or more of SEQ ID NOs:4-6. In some embodiments, the sgRNA sequence targeting the rffT coding region is selected from any one or more of SEQ ID NOs:7-10. In some embodiments, the sgRNA sequence targeting the nlpI coding region is selected from any one or more of SEQ ID NOs:11-13. In some embodiments, the sgRNA sequence targeting the ctP coding region is selected from any one or more of SEQ ID NOs:14-17.

[0086] This application also provides a recombinant Escherichia coli obtained by the above-described method. This recombinant Escherichia coli can be used to produce exogenous vesicles or to load exogenous proteins.

[0087] This application also provides the use of overexpressing bolA protein for increasing the yield of outer membrane vesicles (OMV) in Escherichia coli and / or improving the heterologous protein packaging ability of outer membrane vesicles (OMV).

[0088] The applicant discovered that overexpression of bolA protein in *E. coli* significantly increased outer membrane vesicle (OMV) production compared to overexpression of other proteins. Further research revealed that *E. coli* overexpressing bolA secreted OMV particles with approximately 14-fold, and even 15-fold or 16-fold, higher numbers compared to wild-type OMV; the average particle size of the OMVs was also significantly reduced. Compared to wild-type OMVs, *E. coli* overexpressing bolA exhibited higher levels of heterologous protein packaging, with cargo loading efficiency increased by 10-fold, 11-fold, and even more than 12-fold.

[0089] In this application, there are no major restrictions on the specific selection of the heterologous protein, as long as it can be expressed in outer membrane vesicles. In some embodiments, non-limiting examples of the heterologous protein may be any one or more selected from the group consisting of: ClyA, OmpA, OmpX, OmpC, OmpF, AIDA-I, InaV, FimH, FimA, and NLP42.

[0090] This application also provides a method for improving the packaging ability of heterologous proteins, comprising: This allows bolA to be overexpressed in E. coli, resulting in overexpressed recombinant E. coli. The recombinant Escherichia coli was used to express heterologous proteins.

[0091] Example Specific embodiments of the present application will now be described in more detail with reference to the accompanying drawings. While specific embodiments of the present application are shown in the drawings, it should be understood that the present application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art.

[0092] Experimental methods OMV biogenesis (DNA proxy screening) For the control group, plasmid extraction was performed directly from the library culture. For the experimental group, 50 mL of culture was centrifuged at 8000×g for 20 minutes at 4°C. The supernatant was filtered through a 0.22 μm membrane to remove residual cell debris. OMV was then concentrated by ultracentrifugation at 174900×g (XPN-100 ultracentrifuge; Beckman Coulter 45 Ti rotor) for 2 hours. The resulting OMV was resuspended in 500 μL PBS with ammonium sulfate precipitation, resulting in a concentration approximately 100 times that of the initial culture volume. OMV-related plasmid DNA was extracted after lysis with 1% Triton X-100.

[0093] NGS Library Preparation and Data Analysis Using isolated plasmids as templates, 200 bp sgRNA regions were amplified by PCR. Amplicon sequencing was performed on the Illumina platform by Tsingke Biotech Ltd. Approximately 2 GB of sequencing data was analyzed for each sample. Raw sequencing data was processed by Tsingke Biotech to obtain the sequence of each sgRNA and its corresponding read count. In short, raw sequencing data in FASTQ format was generated on the Illumina platform. To ensure high-quality downstream analysis, raw reads underwent rigorous quality control to obtain clean data, including deletion of adapter sequences, reads containing more than 10% indeterminate bases (N), and low-quality reads. Due to paired-end sequencing, overlapping clean reads were merged into single contiguous fragments based on sequence identity using FLASH software. These merged reads were then aligned and matched against a custom reference sgRNA library. Strict filtering thresholds were applied during alignment to ensure that only perfectly matched (or within defined mismatch tolerances) reads were quantified. Correlation between two biological replicates was analyzed using GraphPad Prism, and differential sgRNA abundance was determined using DESeq2. The mean of sgRNAs was >5, P<0.05, and the highest logarithmic 2 (fold change) value (typically ~200 sgRNAs) was preserved. Genes supported by ≥2 independent sgRNAs were selected as candidate sites.

[0094] OMV characteristics Outer membrane vesicles (OMVs) used for lipid quantification, plasmid DNA quantification, and ClyA-mediated antigen display Western blot analysis were prepared using the same isolation protocol as in the OMV screening model. An alternative isolation protocol was specifically optimized to produce concentrated OMV samples for analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transmission electron microscopy (TEM), and nanoflow cytometry (nFCM), as described below. Briefly, 50 mL of culture was centrifuged at 8000 × g for 20 min at 4 °C. The supernatant was filtered through a 0.45 μm membrane to remove residual cell debris. OMVs were precipitated by adding ammonium sulfate to a final concentration of 400 g / L and then incubated at room temperature for 1 h. Coarse OMV particles were collected by centrifugation at 11000 × g for 30 min at 4 °C. The precipitate was resuspended in 1 mL of 15% (v / v) glycerol and further concentrated by ultracentrifugation at 109000 × g for 1 h. The final OMV precipitate was resuspended in 50 μL of 15% (v / v) glycerol. The resulting concentration was 1000 times the initial culture volume.

[0095] For lipid and plasmid quantification, OMV yield was estimated by measuring total lipid content using the lipophilic dye FM4-64 (3.2 μg / mL), while OMV-encapsulated plasmid DNA was quantified by qPCR targeting the sgRNA region. OMV proteomic profiles were analyzed by SDS-PAGE using a 4-20% Tris-Glycine gradient gel. For Western blot analysis, proteins were transferred to a PVDF membrane and detected using an anti-His6 probe. For morphological observation via TEM, concentrated OMV samples were deposited on a copper grid, negatively stained with 1% (w / v) uranyl acetate, and visualized using a Hitachi HT7800 TEM. Finally, particle size and concentration were analyzed by nFCM using a CytoFLEX Nano flow cytometer (Beckman Coulter) to determine the absolute concentration and particle size distribution of OMV.

[0096] Data Analysis Error bars represent the standard deviations (SDs) from three parallel experiments. P-values ​​were generated using a two-tailed t-test in Microsoft Excel 2016 (Microsoft Corporation).

[0097] Example 1. Construction of a bidirectional whole genome library of Escherichia coli Nissle 1917 based on the VcCAST system 1.1 Design and synthesis of sgRNA libraries The genome of *E. coli* Nissle 1917 (GenBank: NZ_CP007799.1) can be used as a reference for sgRNA design. This application utilizes the INTEGRATE guide RNA tool to design coding and non-coding libraries with “NCC” protospacer adjacent motifs (PAMs). For the knockout (coding) library, open reading frames (ORFs) with a maximum of four and at least two sgRNAs per gene were selected, prioritizing sites closest to the start codon; this resulted in 17,829 unique sgRNAs covering 94.3% of the gene regions. For the overexpression (non-coding) library, sgRNAs were designed to target intergenic regions upstream of the start codon (defined as >50 bp between adjacent ORFs), totaling 25,052 sgRNAs covering 82.2% of the gene regions.

[0098] 1.2 Strains and Plasmids Escherichia coli DH5 was used for molecular cloning and plasmid maintenance. The host strain used in this application was the probiotic chassis Escherichia coli Nissle 1917 (EcN), a strain without native plasmids (EcN ΔpMUT1 ΔpMUT2, commercially available), with a clear genetic background and high safety profile. The strain was typically cultured at 30°C or 37°C in Luria Bertani (LB) broth or LB agar (15 g / L agar). For specific assays, salt-free LB or gastrointestinal symposia were used as described below. Antibiotics were supplemented as needed at the following concentrations: kanamycin (50 g / ml) and streptomycin (50 g / ml).

[0099] Donor plasmids: plasmid L009, used for gene knockout, gene sequence shown in SEQ ID NO:1; plasmid L022, used for gene overexpression, gene sequence shown in SEQ ID NO:2. Both plasmids L009 and L022 were independently constructed in our laboratory and contain a temperature-sensitive replicon, a sacB anti-selection marker, a J23119 strong promoter, and transposase-related expression elements.

[0100] Effect plasmid: L106 vector, used for sgRNA expression, gene sequence as shown in SEQ ID NO:3. The two libraries obtained in Example 1 were commercially synthesized by Genewiz Biotechnology (Suzhou) Co., Ltd. and cloned into the L106 vector backbone (gene sequence as shown in SEQ ID NO:3).

[0101] Specifically, 17,829 sgRNAs for gene knockout (coding region) were cloned into the L106 vector, resulting in 17,829 specific effect plasmids L106-coding. These effect plasmids L106-coding were used in conjunction with the donor plasmid L009 to achieve target gene knockout. 25,053 sgRNAs for gene overexpression (non-coding region) were cloned into the L106 vector, resulting in 25,053 specific effect plasmids L106-non-coding. These effect plasmids L106-non-coding were used in conjunction with the donor plasmid L022 to achieve target gene overexpression. It should be noted that each sgRNA was cloned into the L106 vector in the form of an sgRNA insertion frame as follows; specifically, the sgRNA insertion frame has the following structure: insertion sequence-sgRNA-insertion sequence; that is, an identical insertion sequence is inserted on both sides of the sgRNA, and its sequence is shown in SEQ ID NO:37 (GTGAACTGCCGAGTAGGTAGCTGATAAC); that is: GTGAACTGCCGAGTAGGTAGCTGATAAC-sgRNA-GTGAACTGCCGAGTAGGTAGCTGATAAC.

[0102] 1.3 Construction of whole-genome bidirectional library Preparation of electroporation competent cells: 1) Pick a single colony of EcN-L009 (i.e., carrying donor plasmid L009 (for target gene knockout)) or pick EcN-L022 (i.e., carrying donor plasmid L022 (for target gene overexpression)) into 2 mL of LB medium and culture overnight at 30°C with shaking at 220 rpm. 2) Inoculate 1:100 into 100 mL of salt-free LB medium and wait for OD... 600 When the α-value is 0.4–0.6, incubate the bacterial culture on ice for 10 min, then centrifuge at 4°C and 6000g for 5 min to collect the bacterial cells. 3) Wash the bacterial cells repeatedly with pre-cooled sterile ultrapure water 4 times, and finally resuspend them in 2 mL of ultrapure water, concentrate them 50 times, and place them on ice for later use.

[0103] Electroporation and Genome Integration: 1) Take 400 μL of competent cells and add 200 ng of the corresponding library plasmid (e.g., add effect plasmid L106-coding to competent cells carrying donor plasmid L009; add effect plasmid L106-non-coding to competent cells carrying donor plasmid L022), gently mix, and transfer to a 2 mm electroporation cuvette. 2) Electroporation conditions: voltage 2.5 kV; immediately add 1 mL of antibiotic-free LB medium after electroporation, and incubate at 30°C for 1 h. 3) Spread the revived bacterial culture on LB agar plates containing 50 μg / mL kanamycin + 50 μg / mL streptomycin, and incubate upside down at 30°C for 12–16 h. 4) Collect all colonies on the plates, resuspend them in LB liquid medium, and incubate at 30°C and 220 rpm until the stationary phase, completing VcCAST-mediated site-specific genome integration.

[0104] Elimination of thermosensitive donor plasmids: 1) Transfer the integrated bacterial culture at a ratio of 1:100 to LB medium containing only streptomycin and incubate at 37°C and 220 rpm for 12 h. 2) Repeat the subculture twice to completely eliminate the thermosensitive donor plasmids.

[0105] Library validation and integration: 1) Randomly selected single clones were subjected to colony PCR and Sanger sequencing for validation. The correct integration rate of the gene knockout library was 89.4%, and the correct integration rate of the gene overexpression library was 87.5%.

[0106] 2) Mix the gene knockout library and the gene overexpression library thoroughly at a ratio of 2:3, add 20% (v / v) glycerol to a final concentration, aliquot and store at -80℃ for a long time.

[0107] In this application, the CRISPR-associated transposase (CAST) system mediates efficient, site-specific genome integration without the need for homologous recombination or the introduction of double-strand breaks. Two high-performance CAST systems have been identified: one from *Scytonema hofmanni* (ShCAST), composed of Tn7-like transposase subunits and Cas12k (31); and the other from *Vibrio cholerae* (VcCAST), composed of Tn7-like transposase components (TnsA, TnsB, TnsC, TniQ) and IF CRISPR-Cas complexes (Cas6, Cas7, Cas8). Compared to ShCAST, VcCAST exhibits lower off-target activity and higher genome editing efficiency, making it more suitable for whole-genome functional genomics screening.

[0108] Reference Figure 1 B. The editing platform of this application employs four custom plasmids. Two donor plasmids, L009 and L022, carry a temperature-sensitive origin of replication, sacB, for anti-selection, and a strong J23119 promoter to drive the expression of Cas and Tns proteins, achieving high genome integration efficiency. The donor plasmids are flanked by R57 / L105 sites to minimize polarity effects. Donor plasmid L009 contains a non-coding sequence for gene disruption, while donor plasmid L022 contains a strong J23119 promoter for gene overexpression. Two effector plasmids, L106-coding and L106-non-coding, express sgRNAs targeting both coding and non-coding genomic regions, respectively. The combined use of donor plasmid L009 and effector plasmid L106-coding enables targeted gene knockout, while the combined delivery of donor plasmid L022 and effector plasmid L106-non-coding facilitates gene overexpression.

[0109] To achieve genome-scale editing, this application used the INTEGRATE guide RNA tool to design two sgRNA libraries. (See reference...) Figure 2 A. The sgRNA library contains 17,829 sgRNAs, covering 94.3% of the EcN genes; 94.3% of the genes have more than one sgRNA, of which 93.7% have more than two sgRNAs. Specifically, using the whole genome as a reference, approximately 5.7% of genes have no matching sgRNA; approximately 0.6% of genes each match one independent sgRNA; approximately 0.8% of genes each match two independent sgRNAs; approximately 1.1% of genes each match three independent sgRNAs; and approximately 91.8% of genes each match four independent sgRNAs. (Reference) Figure 2B. The non-coding sgRNA library contains 25,052 sgRNAs, targeting 82.2% of intergenic regions, i.e., regions spanning more than 50 bp between adjacent gene coding sequences. Specifically, using the whole genome as a reference, approximately 17.8% of genes have no matching sgRNA; approximately 4% of genes each match one independent sgRNA; approximately 5.1% of genes each match two independent sgRNAs; approximately 5.7% of genes each match three independent sgRNAs; approximately 5.8% of genes each match four independent sgRNAs; and approximately 61.7% of genes each match more than four independent sgRNAs. (Reference) Figure 1 A. This application first constructs a whole-genome knockout library by pairing donor plasmid L009 with an sgRNA-coding library (effect plasmid L106-coding), and constructs a whole-genome overexpression library by pairing donor plasmid L022 with a non-coding sgRNA library (effect plasmid L106-non-coding). Sanger sequencing of a single clone confirmed that the correct integration rate of the knockout library (corresponding to the result of integrating donor plasmid L009 with effect plasmid L106-coding) was 89.4% (17 / 19), and the correct integration rate of the overexpression library (corresponding to the result of integrating donor plasmid L022 with effect plasmid L106-non-coding) was 87.5% (21 / 24), slightly higher than the genome editing efficiency achieved using a dCas9-based editor previously. Then, based on their respective sizes, the two libraries are combined in a 2:3 ratio to generate the final merged library. Figure 1 A). Notably, the Gini coefficient for sgRNAs increased from 0.18 in the original plasmid library to 0.3–0.4 in the constructed EcN cell library. This increase is more likely due to growth differences induced by genome editing than to the sgRNA plasmid transformation process itself, as the number of clones obtained through transformation provided over 100-fold library coverage. However, the constructed libraries showed good correlation across different biological replicates.

[0110] Example 2. High-throughput screening of OMV high-yield gene DNA-proxy 2.1 Screening Principle Plasmid DNA is more easily encapsulated into outer membrane vesicles (OMVs) than genomic DNA. Therefore, the number of sgRNA plasmid reads in OMVs / the total number of sgRNA plasmid reads in the bacterial cells is used as a quantitative indicator of OMV yield to achieve high-throughput screening.

[0111] 2.2 Experimental Procedure 2.2.1. Library Revival and Cultivation 1) Take the whole genome bidirectional library stored at -80℃ and inoculate it at 1:100 into 50 mL of LB medium containing streptomycin.

[0112] 2) Incubate at 37℃ and 220 rpm with shaking until OD. 600 ≈2.0 (stationary period), with 2 biological replicates.

[0113] 2.2.2. OMV Isolation and Enrichment (for DNA-proxy Screening) 1) Take 50 mL of bacterial culture, centrifuge at 4℃ and 8000 g for 20 min, and carefully aspirate the supernatant.

[0114] 2) The supernatant is filtered through a 0.22μm sterile filter membrane to completely remove residual bacteria.

[0115] 3) Transfer the filtered supernatant to an ultracentrifuge tube, and ultracentrifuge at 4°C and 174900g for 2 hours. Discard the supernatant to obtain OMV precipitate.

[0116] 2.3 OMV lysis and plasmid extraction 1) Resuspend the OMV precipitate in 500 μL PBS, add 1% Triton X-100 to a final concentration, and lyse at room temperature for 30 min.

[0117] 2) Use a plasmid extraction kit to extract plasmid DNA wrapped in OMV and total bacterial plasmid DNA, respectively.

[0118] 2.4 High-throughput sequencing and data analysis 1) Using the extracted plasmid as a template, PCR amplification of the sgRNA region fragment (approximately 200 bp) was performed.

[0119] 2) After purifying the PCR product, construct an NGS library and sequence it on the Illumina platform.

[0120] 3) After quality control, sequence splicing, and alignment, the raw data were subjected to differential enrichment analysis using DESeq2.

[0121] 4) Screening criteria: baseMean>5, P<0.05, log2FC>4, and the same gene is enriched by at least 2 independent sgRNAs.

[0122] 5) A total of 46 candidate genes were finally obtained, as shown in Table 1 below.

[0123] Table 1

[0124] Specifically, refer to Figure 3Bacterial outer membrane vesicles (OMVs), spherical nanoparticles (50-250 nm in diameter) rich in phospholipids (PS), lipoproteins, DNA, and RNA, can activate multiple immune pathways and exhibit enhanced immunogenicity upon antigen display, making them crucial for bacterial physiology and potential therapeutic applications. Conventional whole-genome studies of OMV biogenesis have primarily been limited to transposon (Tn) mutagenesis and laborious LPS quantification. These methods are not only low-throughput but also inherently one-way, limited to loss-of-function perturbations and unable to elicit phenotypes associated with gain-of-function overexpression. Given that plasmid DNA can be efficiently packaged into OMVs, the proportion of sgRNA plasmid reads in OMVs relative to the total bacterial library provides a high-throughput, semi-quantitative reading of the relative OMV production level. Utilizing this novel quantitative strategy, this application performed a whole-genome screening to systematically identify genetic regulators of OMV biogenesis (…). Figure 3 A).

[0125] After screening, the Pearson correlation coefficient between the two biological replicates was 0.785. Figure 5 A) Reference Figure 5 B. The Gini coefficient increased from 0.319 to 0.506 (calculated as the average of the two groups: G=0.319 for Before Rep1 and G=0.453 for After Rep1; G=0.319 for Before Rep2 and G=0.558 for After Rep2), indicating effective enrichment during the screening process. DESeq2 analysis showed that 191 sgRNAs simultaneously met the criteria of baseMean>5, P<0.05, and log2FC>4. After locating these sgRNAs to their genomic positions, 46 genes with more than two sgRNAs were selected as candidate genes (see [reference]). Figure 3 B and Table 1), including well-defined regulating factors such as lpxL, the tol-pal system (tolR, tolB, pal, tolQ), and nlpI, thus verifying the reliability of the screening method in this application. Figure 3 B). Furthermore, this application selected eight candidate genes for reconstruction, with EcN ΔnlpI used as a positive control. (See reference...) Figure 5 D. Quantitative PCR (qPCR) confirmed elevated plasmid DNA levels in OMV isolated from engineered strains. Subsequent lipid quantification confirmed that seven constructs increased OMV production, with only sulA overexpression having no effect on OMV production—a finding that contrasts sharply with previous predictions. Figure 3 C). Among them. Figure 3 The sequences of the sgRNAs involved in the eight reconstruction candidate genes in C and 5D are shown in the sequence listing.

[0126] Example 3. Genotype Reconstruction and Validation of OMV Phenotype and Mechanism in bolA Overexpressing Strains 3.1 Genotype Reconstruction Validation OMV was prepared using the same method used for OMV library screening. The yield of the selected candidate genotypes was characterized by measuring the total lipid content using FM4-64 lipophilic fluorescent dye. It was found that overexpression of bolA had the most significant effect on increasing lipid content.

[0127] 3.2 OMV Preparation (Ammonium sulfate precipitation method, used for nanoflow cytometry, electron microscopy, and SDS-PAGE) Refer to the method described in this article: 1) Inoculate EcN-bolA, WT and ΔnlpI strains into 50 mL LB medium and culture at 37℃ and 220 rpm until they reach the stationary phase.

[0128] 2) Centrifuge at 4℃ and 8000g for 20 minutes, and collect the supernatant.

[0129] 3) The supernatant is filtered through a 0.45μm filter membrane to remove residual bacteria.

[0130] 4) Slowly add ammonium sulfate to the filtrate to a final concentration of 400 g / L, and let it stand at room temperature for 1 hour to precipitate OMV.

[0131] 5) Centrifuge at 4℃ and 11000g for 30 minutes to collect the coarse precipitate of OMV.

[0132] 6) Resuspend the precipitate in 1 mL of PBS containing 15% (v / v) glycerol and centrifuge at 109000 g for 1 h at 4 °C.

[0133] 7) Discard the supernatant, resuspend the OMV precipitate in 50 μL of PBS containing 15% glycerol to obtain an OMV sample that is about 1000 times concentrated for subsequent detection.

[0134] 3.3 OMV Yield, Speciation and Component Detection 1) Nanofluid cytometry (nFCM): The concentration and size distribution of OMV particles were measured using a CytoFLEX Nano flow cytometer. The results showed that the number of OMV particles in the bolA overexpressing strain was about 14 times higher than that in the wild type, and the average particle size was significantly reduced.

[0135] 2) Transmission electron microscopy (TEM): Concentrated OMV samples were dropped onto a copper grid, negatively stained with 1% uranium acetate, and observed under a Hitachi HT7800 electron microscope; the results showed that the OMV density in the bolA overexpression group was significantly higher than that in the wild type.

[0136] 3) SDS-PAGE protein analysis: The composition of OMV proteins was detected by 4%–20% gradient gel electrophoresis; the results showed that the abundance of major outer membrane proteins such as OmpA, OmpC, and OmpF was significantly increased.

[0137] 3.4 Detection of exogenous protein loading capacity 1) The ClyA-mediated antigen display vector was transformed into EcN-bolA and WT strains, and the expression of exogenous proteins was induced by arabinose. Specifically, the ClyA-mediated antigen display vector expressed the OVA antigen polypeptide (amino acid sequence as shown in SEQ ID NO:38) in the plasmid pBAD-clyA-OVA-his6 (nucleic acid sequence as shown in SEQ ID NO:38).

[0138] 2) OMV was extracted using the ammonium sulfate precipitation method and subjected to Western blot and quantitative fluorescence analysis.

[0139] 3) The results showed that the OMV exogenous protein loading efficiency of the bolA overexpression strain was more than 10 times higher than that of the wild type.

[0140] 3.5 Molecular Mechanism Verification 1) Referring to Table 2 below, transcriptome sequencing revealed that bolA overexpression significantly downregulated pal, lpxT, and eptC, and upregulated arnC, arnD, and gmd.

[0141] 2) SDS sensitivity experiment: Refer to Figure 5 E,bolA overexpressing strains showed increased sensitivity to SDS, indicating a weakened connection between the outer membrane and peptidoglycan.

[0142] 3) Verification of patching / knockout: Refer to Figure 4 D. Knocking out arnC or gmd in bolA-overexpressing strains significantly reduced the high OMV production phenotype; knocking out sulA did not affect OMV production.

[0143] 4) Conclusion: bolA strongly promotes OMV biogenesis through a dual mechanism of inhibiting the Tol-Pal system and remodeling the LPS structure.

[0144] Table 2

[0145] Reference Figure 3 C. Among these identified candidate genes, bolA overexpression is the most efficient regulator of OMV biosynthesis, resulting in abnormally high OMV yields, significantly exceeding those observed in nlpI knockout strains, a recognized positive control for enhanced vesicle formation. To fully elucidate the impact of bolA overexpression on OMV characteristics and function, this application provides a comprehensive phenotypic characterization of OMV derived from the bolA-overexpressing EcN strain (EcN). (Refer to...) Figure 4A. SDS-PAGE analysis of purified EcN-OMV showed a significant increase in the abundance of major outer membrane porins, including OmpC, OmpA, and OmpF. These key structural components maintain the integrity of the bacterial outer membrane and mediate nutrient transport. (Reference) Figure 4 B. Consistent with these findings, direct visualization via transmission electron microscopy (TEM) clearly demonstrates that the OMV density in EcN-bolA is higher than that in the wild-type (WT) EcN strain. Figure 4 Nanofluid cytometry (nFCM) quantification of C further confirmed a statistically significant increase in OMV particle count, changing approximately 14-fold compared to the WT control. Interestingly, the mean diameter was significantly reduced compared to wild-type OMV, indicating that bolA overexpression not only promotes OMV biogenesis but also regulates OMV morphogenesis. Figure 4 C). This size reduction may bring functional advantages, such as improved tissue penetration, which is crucial for OMV-based therapeutic applications. Furthermore, to evaluate the practical utility of EcN-OMV as a delivery carrier, this application used ClyA as a carrier protein to evaluate its ability to package heterologous proteins. (See reference...) Figure 5 C and Figure 6 Quantitative analysis of OMV-related cargo proteins using Western blotting and quantitative fluorescence analysis showed that, compared to wild-type OMV, EcN OMV exhibited higher levels of heterologous protein packaging, resulting in a cargo loading efficiency more than 10-fold higher; for example, referencing... Figure 6 One µl of recovered bolA overexpressing OMV produced a band, while 16 µl of wild-type EcN did not. Overall, these comprehensive characterization results confirm that bolA overexpression is a robust strategy for enhancing OMV production, altering OMV structural properties, and improving its cargo packaging capabilities—key features that drive the development of OMV-based engineered therapies.

[0146] To elucidate how BolA mediates vesicle formation in EcN, this application performed transcriptomic analysis and genetic validation. The results showed that, as Figure 5 As shown in E, bolA overexpression significantly suppressed pal, the core component of the Tol-pal complex. This transcriptional repression weakened the connection between the outer membrane and the peptidoglycan layer, as evidenced by the significantly enhanced SDS sensitivity in bolA-overexpressing strains. Figure 5(E). Furthermore, bolA drives extensive LPS remodeling by downregulating lpxT and eptC while upregulating arnC, arnD, and gmd. This mode promises to reduce the negative charge of lipid a and alter the length of LPS glycan chains. In the context of bolA overexpression, knockout of arnC or gmd largely eliminated the high-vesicle phenotype, validating the necessity of LPS remodeling. Notably, although bolA overexpression increased sulA transcription, additional sulA knockout did not affect OMV generation, suggesting that sulA-mediated cell division regulation is not a functional effector. Overall, bolA acts as a master regulator, stimulating OMV formation by simultaneously weakening membrane-cell wall adhesion and remodeling the bacterial surface.

[0147] The sequences used in the above embodiments of this application are shown in the following sequence list. It should be understood that the following sequences are merely exemplary sequences for the embodiments of this application, and not any limitation thereof.

[0148] The description in this disclosure is provided for illustrative and descriptive purposes only and is not intended to be exhaustive or to limit the disclosure to its forms. Many modifications and variations will be apparent to those skilled in the art. The embodiments were chosen and described in order to better illustrate the principles and practical application of this disclosure and to enable those skilled in the art to understand this disclosure and to design various embodiments with various modifications suitable for a particular purpose.

Claims

1. Use of overexpressed and / or underexpressed proteins to increase the production of outer membrane vesicles (OMV) in Escherichia coli; in, The target protein in the overexpressed protein is selected from any one or more of the following group: bolA, qcl, and degQ; The target proteins in the low-expression proteins are rfaI and / or rffT.

2. A method for increasing the yield of outer membrane vesicles (OMV) in Escherichia coli, comprising: Overexpression of any one or more of bolA, qcl, and degQ in E. coli to obtain overexpressed recombinant E. coli; and / or, This resulted in low expression of rfaI and / or rffT in E. coli, yielding recombinant E. coli with low expression.

3. The method according to claim 2, wherein, The method to overexpress any one or more target proteins among bolA, qcl, and degQ in Escherichia coli is to increase the copy number of the gene encoding the target protein, and / or to increase the expression level of the gene encoding the target protein. Preferably, the method for increasing the copy number of the coding gene of the target protein is: increasing the copy number of the coding gene of the target protein on the chromosome of the Escherichia coli, and / or inserting a foreign plasmid containing the coding gene of the target protein; More preferably, the method for increasing the copy number of the gene encoding the target protein on the chromosome in the *E. coli* is selected from: gene homologous recombination and Mu-driven integration; or Preferably, the method for increasing the expression level of the gene encoding the target protein includes: increasing the expression level of the gene encoding the target protein by modifying the expression regulatory region of the gene encoding the target protein; More preferably, the expression regulatory region includes any one or more regulatory elements from the group consisting of: promoters, enhancers, anti-termination signals, ribosome binding sites (RBS), and other expression control elements (e.g., regions where repressors or inducers bind, and / or binding sites of transcription and translation regulatory proteins). In some implementations, the promoter is selected from any one of the J23 series promoters, T7 promoters, lacP promoters, trpP promoters, and λPL promoters.

4. The use according to claim 3, wherein, The method to overexpress any one or more target proteins among bolA, qcl, and degQ in E. coli is to increase the expression level of the gene encoding the target protein by inserting an exogenous promoter. Preferably, the method for inserting the exogenous promoter includes: inserting the exogenous promoter using a CRISPR-associated transposase system.

5. The use according to claim 4, wherein, By simultaneously inserting donor plasmid L022 and effector plasmid L106-noncoding into E. coli, overexpressing recombinant E. coli was obtained. Culture the overexpressing recombinant Escherichia coli; After the donor plasmid L022 and the effect plasmid L106-noncoding were co-expressed in E. coli, the exogenous promoter was inserted into the E. coli via a CRISPR-associated transposase system to overexpress the target protein.

6. The method according to claim 5, wherein, The effect plasmid L106-noncoding contains the L106 vector and sgRNA targeting the non-coding region of the target protein, and the donor plasmid L022 contains the exogenous promoter. Preferably, the target protein is selected from any one or more of the following group: degQ, qcl, and bolA; And / or, The sequence of the donor plasmid L022 is shown in SEQ ID NO:2; and / or The sequence of the L106 vector is shown in SEQ ID NO:3; and / or The sequence of the sgRNA targeting the bolA uncoding region is shown in SEQ ID NO:33 and / or SEQ ID NO:34, and / or The sequences of sgRNAs targeting the qcl untranslated region are shown in SEQ ID NO:31 and / or SEQ ID NO:32, and / or The sgRNA sequence targeting the degQ uncoding region is selected from any one or more of SEQ ID NOs:20~30; preferably SEQ ID NO:

27.

7. The use according to claim 3, wherein, The method for achieving low expression of rfaI and / or rffT proteins in Escherichia coli is selected from: gene knockout, gene silencing, or the introduction of a blocking gene that causes low expression of the target protein into the gene encoding the target protein; Preferably, the method for achieving low expression of rfaI and / or rffT proteins in Escherichia coli is to introduce an expression-blocking gene that causes low expression of the target protein into the gene encoding the target protein. More preferably, the method for introducing a blocking expression gene that causes low expression of the target protein into the coding gene of the target protein is to insert the blocking expression gene using a CRISPR-associated transposase system.

8. The method for inserting the gene blocking expression using the CRISPR-associated transposase system according to claim 7 comprises: Simultaneous recombination of donor plasmid L009 and effect plasmid L106-coding in E. coli yielded low-expression recombinant E. coli; Culture the low-expression recombinant Escherichia coli; After the donor plasmid L009 and effect plasmid L106-coding are co-expressed in the *E. coli*, the blocking expression gene is inserted into the *E. coli* via a CRISPR-associated transposase system to achieve low expression of the target protein.

9. The use according to claim 8, wherein, The effector plasmid L106-coding contains the L106 vector and the sgRNA encoding the target protein, and the donor plasmid L009 contains the gene that blocks expression. Preferably, the target protein is rfaI and / or rffT; and / or The sequence of the donor plasmid L009 is shown in SEQ ID NO:1; and / or The sequence of the L106 vector is shown in SEQ ID NO:3; and / or The sgRNA sequence targeting the rfaI coding region is selected from any one or more of SEQ ID NOs:4-6; and / or The sgRNA sequence targeting the rffT coding region is selected from any one or more of SEQ ID NOs:7~10.

10. A recombinant Escherichia coli, obtained by the method described in any one of claims 2 to 9.